Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
News|Videos|April 8, 2026
7 Cardiology Headlines You Missed in March 2026
Author(s)Abigail Brooks, MA
Fact checked by: Ryan Livingston
March 2026 cardiology updates feature key ACC.26 data, new guidelines, and advances in PAH, AF, hypertension, and lipid management.
Advertisement
Advertisement
March delivered a wave of impactful updates in cardiology, with major trial readouts, regulatory progress, and new guideline recommendations shaping the evolving landscape of cardiovascular care, many of which were highlighted at the American College of Cardiology’s Annual Scientific Session (ACC.26). From pulmonary arterial hypertension (PAH) to atrial fibrillation and hypertrophic cardiomyopathy, the month showcased continued momentum in both therapeutic innovation and clinical strategy.
Related to this article
Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
The FDA set a June 18, 2027, PDUFA date for the subcutaneous GP IIb/IIIa inhibitor, based on phase 3 CeleBrate data.
FDA novel drug approvals in Q3 2026: 22 new therapies, including enlicitide, daraxonrasib, oveporexton, and first treatments for rare diseases.
Advertisement
Advertisement